The 4th EU AML Directive [1], as amended by the 5th EU AML Directive [2], requires each Member State of the EU inter alia to establish registers of beneficial owners (“RBO”) in respect of corporate and other legal entities incorporated within its territory.
By a circular 18/704 of 17 December 2018 (the Circular 18/704), the Luxembourg regulator of the financial sector, the Commission de surveillance du secteur financer (the CSSF) formally endorsed the Guidelines of the European Banking Authority (EBA)
On December 6th 2017, the Luxembourg Parliament published two bills of laws (PL 7216 and PL 7217) aimed at implementing new transparency measures provided by Directive 2015/849 on the prevention of the use of the financial system for the purposes of money laundering or terrorist financing (the AML 4thDirective)
La loi du 14 septembre 2018 relative à une administration transparente et ouverte (ci-après « la Loi »), est entrée en vigueur le 1er janvier 2019.
L’accès aux documents détenus par l’administration est un enjeu institutionnel
Le fait de ne pas respecter les dispositions de l’article L.121-6 (1) et (2) ne constitue pas toujours, à lui seul, une faute grave justifiant un licenciement immédiat. Il convient d’analyser les circonstances dans lesquelles cette omission a eu lieu pour en apprécier le degré de gravité.
Business secrets have long been poorly protected and difficult to defend compared to intellectual property rights (including patents, copyrights and trademarks).
On 11 January 2019, the Council of the Government approved a draft law on the amendment of articles L. 232-2 and L. 233-4 of the Luxembourgish Labour Code and article 28-1 of the amended Law on 16 April 1979 determining the general status of public servants
The law dated 13 January 2019 on the register of beneficial owners has been published on 15 January 2019 in the Luxembourg Official Journal and shall enter into force on 1 March 2019 (the “New Law”).
.jpg "Benoît Kelecom")
Following the announcement of the UK government at the end of last year of its intention to introduce a temporary permissions regime (TPR) for inbound passporting EEA firms and funds,
The Court of Justice of the European Union (CJEU) recently ruled that, unlike medicinal products, medical devices incorporating an ancillary drug substance cannot benefit from supplementary protection certificate (SPC) protection.
